NMS·Healthcare·$1.1B·#96 / 520 in Healthcare
COLL Collegium Pharmaceutical, Inc.
64SOLID
CATEGORY BREAKDOWN
GROWTH38
QUALITY85
STABILITY67
VALUATION98
GOVERNANCE38
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+23.6%
38
> 50% strong
Gross Margin
Revenue retained after direct costs
59.3%
84
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
270.1%
0
< 25% strong
Price / Sales
Market cap relative to trailing revenue
1.4x
98
< 3x strong
Rule of 40
Growth rate plus operating margin
46
86
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.9%
8
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
-19.7%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE COLL WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when COLL's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.